



□ Drug dispensed from a pharmacy (pharmacy benefit)

Setter Health* sunflower health plan.



Kansas Medical Assistance Program
PA Phone 800-933-6593

PA Phone 800-933-6593 PA Fax 800-913-2229

CHECK ONE:

Aetna Better Health of KS PA Pharmacy Phone 855-221-5656 PA Pharmacy Fax 844-807-8453 PA Medical Phone 855-221-5656

PA Medical Fax 855-225-4102

PA Pharmacy Fax 866-399-0929 PA Medical Phone 877-644-4623 PA Medical Fax 888-453-4756 UnitedHealthcare

PA Pharmacy Phone 800-310-6826 PA Pharmacy Fax 866-940-7328 PA Medical Phone 866-604-3267 PA Medical Fax 866-943-6474

Ankylosing Spondylitis Agents PRIOR AUTHORIZATION FORM

Complete form in its entirety and fax to the appropriate plan's PA department. For questions, please call the pharmacy helpdesk specific to the member's plan.

□ Drug administered in an office or outpatient setting (medical benefit)							
MEMBER INFORMATION							
Name:	Name: Med			Medicaid ID:			
Date of Birth:		Gende	er:				
PRESCRIBER INFORMATIO	PRESCRIBER INFORMATION						
Name:		Medic	caid ID:				
NPI:		Phone	2:	Fax:			
Address:		City, S	tate, Zip Code:				
The following medications require Prior Authorization (PA). Medications requiring PA may have to meet clinical and Non-Preferred PA criteria before the claim may be considered for payment. Please provide the required data for the specific drug being requested. Below is a list of links you may find helpful in determining the required information: Clinical PA criteria: http://www.kdheks.gov/hcf/pharmacy/pa_criteria.htm KS Preferred Drug List (PDL): https://www.kdheks.gov/hcf/pharmacy/download/PDLList.pdf Non-Preferred, PA Required PDL criteria: https://www.kdheks.gov/hcf/pharmacy/download/NonPreferred PA Criteria for PDL Drugs.pdf KS NDC lookup tool: https://www.kmap-state-ks.us/Provider/PRICING/NDCSearch.asp Note: https://www.kmap-state-ks.us/Provider/PRICING/HCPCSSearch.asp Note: https://www.kmap-state-ks.us/Provider/PRICING/HCPCSSearch.asp<!--</th-->							
SECTION I: MEDICATION R	•						
Select the appropriate medication(s) for this request: □ Etanercept (Enbrel®, Erelzi™, Eticovo™) □ Infliximab (Remicade®, Inflectra®, Ixifi™, Renflexis®) □ Adalimumab (Humira®, Amjevita™, Cyltezo™, Hyrimoz™) □ Certolizumab (Cimzia®) □ Golimumab (Simponi®) □ Secukinumab (Cosentyx®)							
NDC/HCPCS (J Code)	<u>Strength</u>	<u>Dosage Form</u>	Quantity	<u>Directions for Use</u>			
Indication/Diagnosis:							
Is the requested medication being prescribed for an FDA-approved indication? Indication: ICD-10: Patient's weight: IDD IDS							
- Galerie & Holgiter = 105. = 1/5							

Providers: You are required to return, destroy or further protect any PHI received on this document pertaining to members whom you are not currently treating. Providers are required to immediately destroy any such PHI or safeguard the PHI for as long it is retained. In no event are you permitted to use or re-disclose such PHI.

PATIEN	IT NAME:	ME: MEDICAID ID:				
SECTIO	ON II: NON-PREFERRED MEDICATION	ON				
<u> </u>			red drug list (PDI)?			
	Is the medication requested a non-preferred medication on the Kansas Medicaid preferred drug list (PDL)? KS Preferred Drug List (PDL): http://www.kdheks.gov/hcf/pharmacy/download/PDLList.pdf					
	☐ YES ☐ NO — Proceed to Section III					
	labeling as specified in the Non-	-				
		OL criteria: http://www.kdheks.gov/hcf/pharmacy/downle	oad/NonPreferred_PA_Criteria_for_PDL_Drugs.pdf			
	□ YES □ NO					
	Please submit documentation	of clinical rationale to support the use of the requ	ested non-preferred medication.			
SECTIO	ON III: CLINICAL INFORMATION					
1.		this medication?				
	□ New □ Renewal – Proceed to Section					
2.	Please document the prescribing physician's specialty. □ Rheumatologist □ Other					
		provider consulted with one of the provider special	•			
	·	ument the provider's name, specialty and date of co				
		Specialty:	Date of Consult:			
	□ NO					
3.	•	t has previously tried and failed for treatment of thi				
	*Specify medication name, Action Taken (continue medication, discontinue medication due to inadequate response, contraindication, intolerance) and dates of previous medication trial.					
	Medication name	<u>Action Taken</u>	<u>Dates of trial</u>			
		_	+			
4.	Please list all medications the patien	 t will use in combination with the medication reque	ested for the treatment of this diagnosis.			
	Medication name(s):					
5.						
6.						
	Metric/	Scoring Tool	Value (Include Units if Applicable)			
	ASDAS (Ankylosing Spondylitis Diseas	se Activity Score) score				
	BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) score					
		<u></u>				
SECTIO	ON IV: RENEWAL					
1.		atient has received clinical benefit from continuous	treatment with the requested medication?			
	□ YES □ NO					

Providers: You are required to return, destroy or further protect any PHI received on this document pertaining to members whom you are not currently treating. Providers are required to immediately destroy any such PHI or safeguard the PHI for as long it is retained. In no event are you permitted to use or re-disclose such PHI.

Revised 7/2019 Page 2 of 3

SECTION IV: RENEWAL (continued)

PATIENT	TNAME:	MEDICAID ID:	
2.	ease provide the most recent value for the same metric/scoring tool selected in Section II in original PA request.		
	Metric/Scoring Tool:		
	Value (Include Units if Applicable):		
	Duty		
	Date:		
3.	Please provide the patient's current dose:		
4.	Does the prescriber attest that the patient is not currently on another b	oiologic or Janus kinase (JAK) inhibitor?	
	□ YES □ NO		
PRESCR	RIBER SIGNATURE		
☐ I hav	ve completed all applicable boxes and attached any required docume	entation for review, in addition to signing and dating this form.	
	,	, and a second of the second o	
Prescri	ber or authorized signature	Date	
Prior Authorization of Benefits is not the practice of medicine or the substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications			
	propriate for a patient. Please refer to the applicable plan for the detailed information regarding be	enefits, conditions, limitations, and exclusions. The submitting provider certifies that the	
are ap	propriate for a patient. Please refer to the applicable plan for the detailed information regarding be		

Note: Payment is subject to member eligibility. Authorization does not guarantee payment.

Providers: You are required to return, destroy or further protect any PHI received on this document pertaining to members whom you are not currently treating. Providers are required to immediately destroy any such PHI or safeguard the PHI for as long it is retained. In no event are you permitted to use or re-disclose such PHI.

Revised 7/2019 Page 3 of 3